Time to biochemical relapse after radical prostatectomy and efficacy of salvage radiotherapy in patients with prostate cancer
- 146 Downloads
To investigate the prognostic and therapeutic implications of time to biochemical relapse (BCR) in patients with prostate cancer after radical prostatectomy.
The records of 3210 consecutive men with prostate cancer who underwent radical prostatectomy between January 1998 and June 2013 were retrospectively reviewed. Patients with BCR were divided into three groups based on quartiles of time to BCR, namely an early group (first quartile), an intermediate group (second and third quartiles) and late group (fourth quartile).
817 (25.5%) patients experienced BCR at a median of 24.9 months after surgery. The 8-year rate of distant metastasis-free survival (64.3% vs. 41.3%, p = 0.002) and cancer-specific survival (86.6% vs. 63.4%, p < 0.001) was higher in the salvage radiotherapy (SRT) group than the androgen deprivation therapy (ADT) group in patients with early BCR, whereas those rates (91.3% vs. 87.9%, p = 0.607 and 100.0% vs. 93.1%, p = 0.144, respectively) were similar in patients with late BCR. In the intermediate BCR group, the impact of SRT over ADT on 8-year cancer-specific survival was modest (91.9% vs. 82.3%, p = 0.057) and was limited to patients with pT2 or pT3a disease.
SRT may decrease the risk of distant metastasis and cancer-specific mortality in patients with early BCR. However, a survival benefit for those with late BCR was not apparent. For patients with intermediate BCR, SRT was associated with a cancer-specific survival benefit in patients with pT2 or pT3a disease. Novel genomic tests and imaging modalities may support clinical decision-making in these patients.
KeywordsProstatic neoplasm Prostatectomy Radiotherapy Survival
There were no sources of funding for this study.
Compliance with ethical standards
Conflict of interest
The authors have no conflicts of interest to declare.
- 3.Group IW (2015) The development of intermediate clinical endpoints in cancer of the prostate (ICECaP). J Natl Cancer Inst 107(12):djv261Google Scholar
- 13.Antonarakis ES, Chen Y, Elsamanoudi SI et al (2011) Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database. BJU Int 108(3):378–385CrossRefGoogle Scholar
- 17.Roach III M, Marquez C, Yuo H-S et al (1994) Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 28(1):33–37Google Scholar
- 21.Denham JW, Steigler A, Wilcox C et al (2008) Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial. Lancet Oncol 9(11):1058–1068Google Scholar
- 23.Spratt DE (2018) Evidence-based risk stratification to guide hormone therapy use with salvage radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 102(3):556–560Google Scholar